Pharma Bio Serv Inc (PBSV) 1.1600 $PBSV
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2014
Marketwire - Mon Sep 15, 3:40PM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today net revenues for the three and nine months ended July 31, 2014 were $6.8 and $20.4 million, respectively, a decrease of approximately $1.5 and $3.9 million, or 18.3% and 15.9%, respectively, when compared to the same periods last year. This decrease is mainly attributable to a decline in revenues from projects in the United States, Europe and Puerto Rico consulting markets and the Lab for $0.9, $0.4, $0.1 and $0.2 million, respectively, for the three-month period ended July 31, 2014, and $2.2, $0.9, $0.4 and $0.3 million, respectively, for the nine-month period ended July 31, 2014. Other Company divisions sustained minor revenue gains/losses or remained constant, when compared to the same period last year.
Pharma-Bio Serv to Present at the Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014
Marketwire - Mon Aug 25, 7:06AM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today that the Company will be a featured presenter at the Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014 at the New York Palace Hotel in New York City.
Pharma-Bio Serv Announces Stock Repurchase Program and Results for the Quarter Ended April 30, 2014
Marketwire - Wed Jun 18, 1:22AM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today that its Board of Directors has authorized a stock repurchase program to purchase up to 2 million shares of its outstanding common stock. The timing, manner, price and amount of any repurchases will be at the discretion of the Company, subject to the requirements of the Securities Exchange Act of 1934, as amended, and related rules. The program does not oblige the Company to repurchase any shares and it may be modified, suspended or terminated at any time and for any reason. No shares will be repurchased directly from directors or officers of the Company.
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2014
Marketwire - Mon Mar 17, 3:15PM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today net revenues for the three months ended January 31, 2014 of $7.0 million, a decrease of approximately $0.6 million, or 8%, when compared to the same period in 2013. This decrease is mainly attributable to a decline in revenues from projects of $0.4 and $0.2 million in the United States and Europe consulting markets, respectively. The Company continues investing in its global business development and operations in order to diversify its market and customer base.
Be Smart and Skip Bank Queues
All Africa Global Media - Tue Feb 25, 7:02AM CST
As the end of the month draws nearer, bank customers are being encouraged to skip the queues by banking smartly with the latest technology.
Pharma-Bio Serv Announces Record Total Net Revenues of $33.1 Million and Record Net Income of $4.9 Million for the Year Ended October 31, 2013
Marketwire - Wed Jan 29, 3:25PM CST
Pharma-Bio Serv (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, recently announced record total net revenues of $33.1 million for the year ended October 31, 2013, an increase of approximately $3.8 million, or 13%, compared to 2012. The United States consulting market division and the Lab led the revenue improvement for the year ended October 31, 2013 with an increase in revenues of $2.2 and $1.0 million, respectively, when compared to 2012. Other company divisions sustained minor revenue changes or remained constant, when compared to 2012. The revenue growth, offset by the increase in operational support and business development expenses, resulted in record net income of approximately $4.9 million for the year ended October 31, 2013, an increase of $0.2 million, or 4.7%, when compared with 2012.
Pharma-Bio Serv to Present at Sidoti's Eighth Semi-Annual New York Micro-Cap Conference
Marketwire - Fri Jan 10, 3:38PM CST
Pharma-Bio Serv (OTCQB: PBSV), a global compliance and validation services consulting solutions provider, announced today that it will be presenting at Sidoti & Company's Eighth Semi-Annual Micro-Cap Conference on Monday, January 13, 2014 at 8:00 am at the Grand Hyatt New York Hotel in midtown Manhattan.
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2013
Marketwire - Fri Jun 14, 3:10PM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a global compliance and validation services consulting solutions provider, announced net revenues for the three and six months ended April 30, 2013 of $8.3 and $15.9 million, an increase of approximately $1.2 and $2.5 million, or 17% and 18%, respectively, when compared to the same periods last year.
Market Maker Surveillance Report. TTNP, MEMS, ECT, GMXR, MTSL, PBSV, Losing Stocks With Lowest Price Friction For Tuesday, March 19th 2013
M2 - Wed Mar 20, 3:42AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3961 companies with "abnormal" market making, 2118 companies with positive Friction Factors and 3315 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Titan Pharmaceuticals Inc (OTC:TTNP), Memsic Inc (NASDAQ:MEMS), ECA MARCELLUS TRUST I (NYSE:ECT), GMX Resources Inc (NYSE:GMXR), Mer Telemanagement Solutions Ltd (NASDAQ:MTSL), PHARMA-BIO SERV INC (OTC
BSV). To access Friction Factor, Naked Short Data and SqueezeTri
Market Maker Surveillance Report. ICAD, AMRI, CACH, OKOFF, PBSV, RPXC, Winning Stocks With Lowest Price Friction For Wednesday, February 13th 2013
M2 - Thu Feb 14, 2:48AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3926 companies with "abnormal" market making, 2845 companies with positive Friction Factors and 2433 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. iCAD Inc (NASDAQ:ICAD), Albany Molecular Research Inc (NASDAQ:AMRI), Cache Inc (NASDAQ:CACH), ORKO SILVER CORP (OTC:OKOFF), PHARMA-BIO SERV INC (OTC BSV), RPX CORP (NASDAQ:RPXC). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2014
Marketwire - Mon Sep 15, 3:40PM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today net revenues for the three and nine months ended July 31, 2014 were $6.8 and $20.4 million, respectively, a decrease of approximately $1.5 and $3.9 million, or 18.3% and 15.9%, respectively, when compared to the same periods last year. This decrease is mainly attributable to a decline in revenues from projects in the United States, Europe and Puerto Rico consulting markets and the Lab for $0.9, $0.4, $0.1 and $0.2 million, respectively, for the three-month period ended July 31, 2014, and $2.2, $0.9, $0.4 and $0.3 million, respectively, for the nine-month period ended July 31, 2014. Other Company divisions sustained minor revenue gains/losses or remained constant, when compared to the same period last year.
Pharma-Bio Serv to Present at the Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014
Marketwire - Mon Aug 25, 7:06AM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today that the Company will be a featured presenter at the Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014 at the New York Palace Hotel in New York City.
Pharma-Bio Serv Announces Stock Repurchase Program and Results for the Quarter Ended April 30, 2014
Marketwire - Wed Jun 18, 1:22AM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today that its Board of Directors has authorized a stock repurchase program to purchase up to 2 million shares of its outstanding common stock. The timing, manner, price and amount of any repurchases will be at the discretion of the Company, subject to the requirements of the Securities Exchange Act of 1934, as amended, and related rules. The program does not oblige the Company to repurchase any shares and it may be modified, suspended or terminated at any time and for any reason. No shares will be repurchased directly from directors or officers of the Company.
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2014
Marketwire - Mon Mar 17, 3:15PM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today net revenues for the three months ended January 31, 2014 of $7.0 million, a decrease of approximately $0.6 million, or 8%, when compared to the same period in 2013. This decrease is mainly attributable to a decline in revenues from projects of $0.4 and $0.2 million in the United States and Europe consulting markets, respectively. The Company continues investing in its global business development and operations in order to diversify its market and customer base.
Be Smart and Skip Bank Queues
All Africa Global Media - Tue Feb 25, 7:02AM CST
As the end of the month draws nearer, bank customers are being encouraged to skip the queues by banking smartly with the latest technology.
Pharma-Bio Serv Announces Record Total Net Revenues of $33.1 Million and Record Net Income of $4.9 Million for the Year Ended October 31, 2013
Marketwire - Wed Jan 29, 3:25PM CST
Pharma-Bio Serv (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, recently announced record total net revenues of $33.1 million for the year ended October 31, 2013, an increase of approximately $3.8 million, or 13%, compared to 2012. The United States consulting market division and the Lab led the revenue improvement for the year ended October 31, 2013 with an increase in revenues of $2.2 and $1.0 million, respectively, when compared to 2012. Other company divisions sustained minor revenue changes or remained constant, when compared to 2012. The revenue growth, offset by the increase in operational support and business development expenses, resulted in record net income of approximately $4.9 million for the year ended October 31, 2013, an increase of $0.2 million, or 4.7%, when compared with 2012.
Pharma-Bio Serv to Present at Sidoti's Eighth Semi-Annual New York Micro-Cap Conference
Marketwire - Fri Jan 10, 3:38PM CST
Pharma-Bio Serv (OTCQB: PBSV), a global compliance and validation services consulting solutions provider, announced today that it will be presenting at Sidoti & Company's Eighth Semi-Annual Micro-Cap Conference on Monday, January 13, 2014 at 8:00 am at the Grand Hyatt New York Hotel in midtown Manhattan.
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2013
Marketwire - Fri Jun 14, 3:10PM CDT
Pharma-Bio Serv. (OTCQB: PBSV), a global compliance and validation services consulting solutions provider, announced net revenues for the three and six months ended April 30, 2013 of $8.3 and $15.9 million, an increase of approximately $1.2 and $2.5 million, or 17% and 18%, respectively, when compared to the same periods last year.
Market Maker Surveillance Report. TTNP, MEMS, ECT, GMXR, MTSL, PBSV, Losing Stocks With Lowest Price Friction For Tuesday, March 19th 2013
M2 - Wed Mar 20, 3:42AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3961 companies with "abnormal" market making, 2118 companies with positive Friction Factors and 3315 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Titan Pharmaceuticals Inc (OTC:TTNP), Memsic Inc (NASDAQ:MEMS), ECA MARCELLUS TRUST I (NYSE:ECT), GMX Resources Inc (NYSE:GMXR), Mer Telemanagement Solutions Ltd (NASDAQ:MTSL), PHARMA-BIO SERV INC (OTC
BSV). To access Friction Factor, Naked Short Data and SqueezeTri Market Maker Surveillance Report. ICAD, AMRI, CACH, OKOFF, PBSV, RPXC, Winning Stocks With Lowest Price Friction For Wednesday, February 13th 2013
M2 - Thu Feb 14, 2:48AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3926 companies with "abnormal" market making, 2845 companies with positive Friction Factors and 2433 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. iCAD Inc (NASDAQ:ICAD), Albany Molecular Research Inc (NASDAQ:AMRI), Cache Inc (NASDAQ:CACH), ORKO SILVER CORP (OTC:OKOFF), PHARMA-BIO SERV INC (OTC
BSV), RPX CORP (NASDAQ:RPXC). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks 
